Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Myelofibrosis
NCT00931762Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2009
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Novartis. Primary endpoint: Overall Response Rate at 2 years. Started Aug 2009; status: terminated.
02
Drugs
panobinostat
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT00931762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931762.